How to Treat Prostate Cancer With Androgen Deprivation and Minimize Cardiovascular Risk

• Androgen deprivation therapy is associated with metabolic derangements due to profound hypogonadism that can increase the risk of CV disease in prostate cancer survivors. • Therapeutic advances have resulted in prolonged patient exposure to androgen deprivation therapy, thereby increasing CV complications for many prostate cancer survivors. • A systematic approach to monitoring and addressing reversible CV risk factors and purposeful engagement in multidisciplinary care between oncologists, urologists, and cardiologists is critical to optimizing CV outcomes in men with prostate cancer.